GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

The transcript discusses GSK's acquisition of US cancer biotech IDRX for up to $1.15 billion, highlighting their oncology strategy and pipeline development. GSK plans to launch new cancer drugs, including a promising multiple myeloma treatment. The company emphasizes its focus on specialty medicines and oncology, aiming to expand its portfolio with innovative solutions. GSK's deal-making strategy involves bolt-on acquisitions to enhance its pipeline. The US market is a priority, with significant investments in R&D and manufacturing. GSK remains committed to vaccines and navigating potential challenges with the Trump administration.

In what ways does GSK aim to address unmet needs in oncology?

How does GSK's deal-making strategy reflect its goals in the oncology sector?

What role does the US market play in GSK's overall business strategy?